ClinicalTrials.gg
CompletedNCT01244984Updated Jan 11, 2017Results posted

A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma

A Phase 3 interventional study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder in Asthma, sponsored by GlaxoSmithKline. Completed at 30 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-11.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
243
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
17th of 40
243 · median 102
Started
2010
with 6 others
Phase 3
14 of 40
none open now
Registered
18th of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 17th largest by enrollment, is one of 7 that started in 2010, is one of 14 in phase 3, and was the 18th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

The primary purpose of the study is to assess the safety and tolerability of 52-week teatment with fluticasone furoate/GW642444 inhalation powder once-daily and FF inhalation powder once-daily in Japanese adult subjects with asthma.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma
  • Fluticasone furoate
  • GW642444
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Out patient at least 18 years of age
  • Both genderds; females of must be willing to use method
  • A diagnosis of asthma at least 6 months prior to Screening
  • A best of at least 50% of the predicted nomal value at Screening
  • Subjects have been receiving maintanance therapy for asthma, for at least 4 weeks prior to Screening

Exclusion criteria

Exclusion Criteria:

  • History of life-threating asthma
  • Respiratory infection or oral candidiasis
  • Asthma exacerbation within 12 weeks
  • Concurrent respiratory disease or other disease that would confound study participation or affect subject safety
  • Allergies to study drugs, study drugs7 , medications related to study drugs
  • Taking another medication or medication prohibited for use during this study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
243 participants (actual)

Study arms

  • Experimental
    Fluticasone Furoate/GW642444

    Combination inhaled corticosteroid and long-acting beta2-agonist

    Drug: Fluticasone Furoate/GW642444 Inhalation Powder

  • Experimental
    Fluticasone Furoate

    Inhaled corticosteroid

    Drug: Fluticasone Furoate Inhalation Powder

Interventions

  • DrugFluticasone Furoate/GW642444 Inhalation Powder

    Drug pages: Fluticasone furoate · Vilanterol

    Fluticasone Furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks

  • DrugFluticasone Furoate Inhalation Powder

    Fluticasone Furoate inhalation powder inhaled orally once daily for 52 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE)

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold \>=5%) and SAE.

    Time frame: From the start of investigational product to the last dose of treatment (up to Week 52/Withdrawal [WD])

Secondary outcomes

  1. Laboratory Parameters of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

    Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

    Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD

  2. Laboratory Parameters of Eosinophils, Platelet Count, White Blood Cell (WBC), and Total Neutrophils at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

    Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

    Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD

  3. Laboratory Parameter of Hemoglobin at Baseline (Week -2), Week 12,Week 24, and Week 52/WD

    Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

    Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD

  4. Laboratory Parameter of Hematocrit at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

    Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

    Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD

  5. Laboratory Parameter of Red Blood Cell Count at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

    Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

    Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD

  6. Laboratory Parameter of Albumin and Total Protein (TP) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

    Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

    Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD

  7. Laboratory Parameter of Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase, Gamma Glutamyl Transferase (GGT), and Lactate Dehydrogenase (LDH) at BL (Week -2), Week 12, Week 24, and Week 52/WD

    Blood samples were collected for measurement at the following scheduled time points: Baseline (BL) (Week -2), Week 12, Week 24 and Week 52/WD.

    Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD

  8. Laboratory Parameter of Bilirubin (Direct [BD], Indirect [BI], Total [BT], Creatinine, and Uric Acid at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

    Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

    Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD

  9. Laboratory Parameter of Chloride, Carbon Dioxide Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

    Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

    Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD

  10. Laboratory Parameter of Urine Potential of Hydrogen (pH) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

    Urine samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

    Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD

  11. Laboratory Parameter of Urine Specific Gravity (USG) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

    Urine samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

    Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD

  12. Number of Participants for the Indicated Uninalysis Parameters Tested by Dipstick at Baseline (BL), Week 12, Week 24, and Week 52/WD

    Urinalysis parameters included: Urine Occult Blood (UOB), Urine Glucose (UG), Urine Ketones (UK), Urine Protein (UP), and Urine Leukocyte Esterase test for detecting White Blood Cell (UWBC). The dipstick was a strip used to detect the presence or absence of these parameters in the urine sample. The dipstick test gives results in a semi-quantitative manner, and results can be read as negative (Neg), Trace (TRA), 1+, 2+, and 3+, indicating proportional concentrations in the urine sample. Data are reported as the number of participants who had neg, trace, 1+, 2+, and 3+ levels at Baseline (Week -2) and Week 52/WD.

    Time frame: Baseline (Week -2), Week 12, Week 24, and Week 52/WD

  13. Change From Baseline in the 24-hour Urinary Cortisol Excretion

    Urine samples were collected for measurement of urinary cortisol excretion at the following scheduled time points: Baseline (Week 0), Week 24, and Week 52/WD. The 24-hour urinary cortisol excretion was calculated by multiplying the total volume of urine by the concentration of urinary cortisol. Cortisol is a hormone released from the adrenal gland that helps in fat, protein, and carbohydrate metabolism. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline.

    Time frame: Baseline (Week 0), Week 24, and Week 52/WD

  14. Change From Baseline in Blood Pressure

    Blood pressure measurement included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Baseline (Week 0), Weeks 12, 24 and Week 52/WD. Blood pressure was measured in a sitting position after a participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (Week 0), Week 12, Week 24, and Week 52/WD

  15. Change From Baseline in Heart Rate (HR)

    Heart rate was measured in a sitting position after a participant was kept at rest for at least 5 minutes at Baseline (Week 0), Weeks 12, 24 and Week 52/WD. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (Week 0), Week 12, Week 24, and Week 52/WD

  16. Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings

    A 12-lead ECG was recorded in a supine position after the participant was kept at rest in this position for at least 5 minutes at assessment time points (Baseline\[Week -2\], Week 12, 24 and Week 52/WD) in the treatment period. Data are presented for clinically significant (CS) as well as not clinically significant (NCS) abnormal (Abn) findings. Any abnormal ECG, including those that worsen from Baseline, and determined clinically significant by the assessment of the investigator were recorded as CS.

    Time frame: Week 12, Week 24, and Week 52/WD

  17. Number of Participants With Severe Asthma Exacerbation During the Study Treatment

    A severe asthma exacerbation is defined as the deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. Courses of corticosteroids separated by 1 week or more were treated as separate severe exacerbations.

    Time frame: Baseline up to Week 52

  18. Change From Baseline in Diary Data - Morning (AM) Peak Expiratory Flow (PEF) and Evening (PM) PEF During the Study Treatment

    Change from Baseline in AM and PM PEF at 52 weeks of evaluation period during study treatment was recorded in the dairy record card. The Baseline value was calculated as the mean of all available data recorded during the7 days immediately prior to the treatment start date (including Day 1: Day 1 is treatment start date). The PEF is defined as the greatest rate of airflow that can be achieved during forced exhalation beginning with the lungs fully inflated.

    Time frame: Baseline up to Week 52

  19. Change From Baseline in Asthma Symptom Score During the Study Treatment

    The Baseline value was calculated as the mean of all available data recorded during the 7 days immediately prior to Visit 2 (treatment assignment visit). Participants entered their asthma symptom score in the patient diary twice daily (morning and evening). Daytime asthma symptom scores: 0-no asthma symptoms, 1-one episode of short-time asthma symptoms, 2-two or more episodes of short-time asthma symptoms, 3-asthma symptoms occurring during most part of daytime without interference with daily life activities, 4-asthma symptoms occurring during most part of daytime with interference with daily life activities, 5-severe asthma symptoms that disable working or daily life activities. Nighttime asthma symptom scores: 0-no asthma symptoms, 1-one awakening due to asthma symptoms, 2-two or more awakenings due to asthma symptoms, 3-asthma symptoms almost prevented the participant from sleeping, 4-severe asthma symptoms completely prevented from sleeping.

    Time frame: Baseline up to Week 52

  20. Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the Study Treatment

    Participants who were symptom free for 24-hours were assessed. Change from Baseline is calculated as the value at Week 52 minus the value at Baseline.

    Time frame: Baseline up to Week 52

  21. Change From Baseline in the Percentage of Rescue-free 24-hour Periods

    The time span during which the participants did not have to take any rescue medication (medication intended to relieve symptoms immediately) was considered as a rescue free period. Change from Baseline is calculated as the value at Week 52 minus the value at Baseline.

    Time frame: Baseline up to Week 52

  22. Number of Rescue Medication Inhalations

    Salbutamol inhaler was used as the rescue medication. Participants entered the number of rescue medication inhalations in the patient diary twice daily (morning and evening).

    Time frame: Baseline up to Week 52

07

Results

Posted Aug 9, 2013

Participant flow

Participant flow — Overall Study
MilestoneFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Started609390
Completed557986
Not completed5144
Withdrew: Adverse event2112
Withdrew: Protocol violation100
Withdrew: Protocol defined stopping criteria110
Withdrew: Withdrawal by subject122

Outcome measures

PrimaryNumber of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE)

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold \>=5%) and SAE.

Time frame:
From the start of investigational product to the last dose of treatment (up to Week 52/Withdrawal [WD])
Reported as:
Number · Participants
Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE)
ParticipantsFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Any SAE471
Any Non-serious AE527772
SecondaryLaboratory Parameters of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

Time frame:
Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Reported as:
Mean · Percentage
Laboratory Parameters of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
PercentageFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Basophils, Baseline, n=60,93,900.78 ± 0.5090.71 ± 0.4190.79 ± 0.508
Basophils, Week 12, n=58, 90, 870.76 ± 0.4730.67 ± 0.4140.79 ± 0.542
Basophils, Week 24, n=58, 83, 860.74 ± 0.5100.66 ± 0.3920.72 ± 0.408
Basophils, Week 52/WD, n=60, 90, 890.77 ± 0.5100.64 ± 0.3830.72 ± 0.482
Eosinophils, Baseline, n=60,93,905.59 ± 4.4765.03 ± 3.8435.32 ± 3.167
Eosinophils, Week 12, n=58, 90, 875.22 ± 3.2574.01 ± 3.1124.90 ± 3.496
Eosinophils, Week 24, n=58, 83, 864.88 ± 3.6784.00 ± 2.7534.37 ± 3.061
Eosinophils, Week 52/WD, n=60, 90, 894.89 ± 3.9814.27 ± 3.2474.60 ± 3.090
Lymphocytes, Baseline, n=60, 93, 9030.49 ± 5.94830.95 ± 7.50431.26 ± 6.150
Lymphocytes, Week 12, n=58, 90, 8729.22 ± 6.89129.15 ± 6.37829.35 ± 7.274
Lymphocytes , Week 24, n=58, 83, 8629.06 ± 6.26928.40 ± 6.28228.83 ± 6.343
Lymphocytes, Week 52/WD, n=60, 90, 8930.01 ± 6.70227.67 ± 7.91329.04 ± 7.047
Monocytes, Baseline, n=60,93,905.23 ± 1.3075.39 ± 1.4085.35 ± 1.442
Monocytes, Week 12, n=58, 90, 875.65 ± 1.1875.61 ± 1.6265.65 ± 1.639
Monocytes, Week 24, n=58, 83, 865.51 ± 1.5715.52 ± 1.3215.41 ± 1.370
Monocytes, Week 52/WD, n=60, 90, 895.59 ± 1.6375.72 ± 1.3665.59 ± 1.516
Total neutrophils, Baseline, n=60,93,9057.91 ± 8.06457.92 ± 8.10357.28 ± 7.467
Total neutrophils, Week 12, n=58, 90, 8759.14 ± 7.78560.57 ± 7.47459.31 ± 8.642
Total neutrophils, Week 24, n=58, 83, 8659.82 ± 7.89361.37 ± 6.79060.64 ± 7.358
Total neutrophils, Week 52/WD, n=60, 90, 8958.54 ± 8.91061.70 ± 8.32660.05 ± 7.883
SecondaryLaboratory Parameters of Eosinophils, Platelet Count, White Blood Cell (WBC), and Total Neutrophils at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

Time frame:
Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Reported as:
Mean · 10^9 per liter (Gi/L)
Laboratory Parameters of Eosinophils, Platelet Count, White Blood Cell (WBC), and Total Neutrophils at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
10^9 per liter (Gi/L)FF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Eosinophils, Baseline, n=60, 93, 900.338 ± 0.25140.323 ± 0.25910.323 ± 0.2042
Eosinophils, Week 12, n=58, 90, 870.306 ± 0.21060.245 ± 0.20570.286 ± 0.2154
Eosinophils, Week 24, n=58, 83, 860.282 ± 0.22440.247 ± 0.18640.256 ± 0.1907
Eosinophils, Week 52/WD, n=60, 90, 890.290 ± 0.23990.281 ± 0.23320.285 ± 0.2032
Platelet count, Baseline, n=60, 93, 90252.4 ± 53.41257.1 ± 64.98254.1 ± 60.77
Platelet count, Week 12, n=58, 90, 87263.9 ± 62.25269.3 ± 60.55259.0 ± 54.00
Platelet count, Week 24, n=58, 83, 86261.1 ± 62.25270.2 ± 66.60260.1 ± 58.84
Platelet count, Week 52/WD, n=60, 90, 89267.2 ± 54.93276.7 ± 68.64270.3 ± 63.75
WBC, Baseline, n=60, 93, 906.24 ± 1.7166.39 ± 1.5036.13 ± 1.495
WBC, Week 12, n=58, 90, 875.90 ± 1.6426.11 ± 1.4625.95 ± 1.636
WBC, Week 24, n=58, 83, 865.86 ± 1.5416.19 ± 1.7436.01 ± 1.564
WBC, Week 52/WD, n=60, 90, 896.11 ± 1.6256.45 ± 1.5306.24 ± 1.511
Total neutrophils, Baseline, n=60, 93, 903.661 ± 1.34443.734 ± 1.24463.536 ± 1.1080
Total neutrophils, Week 12, n=58, 90, 873.522 ± 1.21403.729 ± 1.11313.567 ± 1.2419
Total neutrophils, Week 24, n=58, 83, 863.522 ± 1.11863.833 ± 1.28123.690 ± 1.2837
Total neutrophils, Week 52/WD, n=60, 90, 893.585 ± 1.25704.010 ± 1.24223.795 ± 1.2221
SecondaryLaboratory Parameter of Hemoglobin at Baseline (Week -2), Week 12,Week 24, and Week 52/WD

Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

Time frame:
Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Reported as:
Mean · Grams per liter (g/L)
Laboratory Parameter of Hemoglobin at Baseline (Week -2), Week 12,Week 24, and Week 52/WD
Grams per liter (g/L)FF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Baseline, n=60, 93, 90135.7 ± 15.88141.1 ± 16.34138.6 ± 15.61
Week 12, n=58, 90, 87138.2 ± 15.10140.6 ± 15.58139.1 ± 14.47
Week 24, n=58, 83, 86137.4 ± 15.45140.8 ± 15.99139.0 ± 14.92
Week 52/WD, n=60, 90, 89136.4 ± 14.16139.0 ± 15.91136.7 ± 15.62
SecondaryLaboratory Parameter of Hematocrit at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

Time frame:
Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Reported as:
Mean · Proportions of I
Laboratory Parameter of Hematocrit at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Proportions of IFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Baseline, n=60, 93, 900.4214 ± 0.044290.4374 ± 0.044170.4319 ± 0.04090
Week 12, n=58, 90, 870.4288 ± 0.042240.4325 ± 0.041990.4283 ± 0.03870
Week 24, n=58, 83, 860.4238 ± 0.042280.4333 ± 0.042770.4288 ± 0.03858
Week 52/WD, n=60, 90, 890.4194 ± 0.039210.4272 ± 0.043670.4215 ± 0.04138
SecondaryLaboratory Parameter of Red Blood Cell Count at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

Time frame:
Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Reported as:
Mean · 10^12 per liter (Ti/L)
Laboratory Parameter of Red Blood Cell Count at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
10^12 per liter (Ti/L)FF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Baseline, n=60, 93, 904.557 ± 0.49874.714 ± 0.48044.689 ± 0.4493
Week 12, n=58, 90, 874.656 ± 0.45404.685 ± 0.48884.696 ± 0.4267
Week 24, n=58, 83, 864.626 ± 0.46794.687 ± 0.48984.681 ± 0.4357
Week 52/WD, n=60, 90, 894.603 ± 0.44694.671 ± 0.50824.664 ± 0.4643
SecondaryLaboratory Parameter of Albumin and Total Protein (TP) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

Time frame:
Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Reported as:
Mean · g/L
Laboratory Parameter of Albumin and Total Protein (TP) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
g/LFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Albumin, Baseline, n=60, 93, 9044.3 ± 2.7244.8 ± 2.5944.7 ± 2.86
Albumin, Week 12, n=58, 90, 8744.3 ± 2.3744.1 ± 2.6644.3 ± 2.69
Albumin, Week 24, n=58, 83, 8643.6 ± 2.5243.9 ± 2.6743.7 ± 2.69
Albumin, Week 52/WD, n=60, 90, 8943.5 ± 2.4943.4 ± 3.0343.8 ± 2.72
TP, Baseline, n=60, 93, 9073.3 ± 4.3673.6 ± 3.6274.6 ± 4.08
TP, Week 12, n=58, 90, 8773.8 ± 3.7073.0 ± 3.8374.4 ± 4.56
TP, Week 24, n=58, 83, 8672.3 ± 4.4972.4 ± 3.9273.3 ± 3.78
TP, Week 52/WD, n=60, 90, 8971.5 ± 3.5571.4 ± 3.6072.5 ± 4.15
SecondaryLaboratory Parameter of Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase, Gamma Glutamyl Transferase (GGT), and Lactate Dehydrogenase (LDH) at BL (Week -2), Week 12, Week 24, and Week 52/WD

Blood samples were collected for measurement at the following scheduled time points: Baseline (BL) (Week -2), Week 12, Week 24 and Week 52/WD.

Time frame:
Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Reported as:
Mean · International unit per liter (IU/L)
Laboratory Parameter of Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase, Gamma Glutamyl Transferase (GGT), and Lactate Dehydrogenase (LDH) at BL (Week -2), Week 12, Week 24, and Week 52/WD
International unit per liter (IU/L)FF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
AP, Baseline, n=60, 93, 90209.9 ± 57.34222.7 ± 62.97217.1 ± 64.13
AP, Week 12, n=58, 90, 87217.9 ± 56.39214.9 ± 56.73220.3 ± 59.92
AP, Week 24, n=58, 83, 86212.3 ± 59.48216.4 ± 57.33215.9 ± 58.96
AP, Week 52/WD, n=60, 90, 89223.1 ± 64.76219.9 ± 60.27217.0 ± 57.89
ALT, Baseline, n=60, 93, 9019.0 ± 9.6922.3 ± 14.4621.9 ± 16.43
ALT, Week 12, n=58, 90, 8724.1 ± 23.1221.3 ± 11.3920.7 ± 11.44
ALT, Week 24, n=58, 83, 8619.0 ± 11.5220.7 ± 10.4520.1 ± 10.35
ALT, Week 52/WD, n=60, 90, 8921.8 ± 12.4623.2 ± 13.5223.0 ± 14.11
AST, Baseline, n=60, 93, 9020.0 ± 5.4822.0 ± 7.5021.5 ± 8.99
AST, Week 12, n=58, 90, 8723.2 ± 10.0822.0 ± 7.5921.7 ± 6.90
AST, Week 24, n=58, 83, 8620.1 ± 5.7221.2 ± 7.2920.6 ± 6.02
AST, Week 52/WD, n=60, 90, 8923.5 ± 9.4723.3 ± 7.5322.8 ± 6.75
Creatine Kinase, Baseline, n=60, 93, 90111.9 ± 56.95149.8 ± 134.73104.0 ± 45.88
Creatine Kinase, Week 12, n=58, 90, 87118.9 ± 84.32134.0 ± 114.9297.4 ± 39.32
Creatine Kinase, Week 24, n=58, 83, 86115.4 ± 77.09131.9 ± 118.86103.0 ± 58.40
Creatine Kinase, Week 52/WD, n=60, 90, 89105.3 ± 48.78126.6 ± 105.2499.9 ± 48.96
GGT, Baseline, n=60, 93, 9025.4 ± 14.0434.9 ± 42.7030.0 ± 28.96
GGT, Week 12, n=58, 90, 8728.1 ± 15.2931.0 ± 32.2128.2 ± 24.60
GGT, Week 24, n=58, 83, 8624.7 ± 14.7330.8 ± 39.6626.5 ± 22.28
GGT, Week 52/WD, n=60, 90, 8928.2 ± 16.8534.6 ± 48.0328.9 ± 24.59
LDH, Baseline, n=60, 93, 90176.7 ± 23.78186.9 ± 34.40175.3 ± 27.97
LDH, Week 12, n=58, 90, 87180.8 ± 32.66185.7 ± 37.83175.1 ± 28.03
LDH, Week 24, n=58, 83, 86175.3 ± 29.35184.4 ± 36.45174.3 ± 27.84
LDH, Week 52/WD, n=60, 90, 89179.5 ± 31.50188.1 ± 39.96177.9 ± 29.66
SecondaryLaboratory Parameter of Bilirubin (Direct [BD], Indirect [BI], Total [BT], Creatinine, and Uric Acid at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

Time frame:
Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Reported as:
Mean · Micromoles per Liter (µmol/L)
Laboratory Parameter of Bilirubin (Direct [BD], Indirect [BI], Total [BT], Creatinine, and Uric Acid at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Micromoles per Liter (µmol/L)FF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
direct [BD], Baseline, n=60, 93, 903.220 ± 1.44593.236 ± 1.58383.401 ± 1.7851
direct [BD], Week 12, n=58, 90, 872.948 ± 1.27293.230 ± 1.54753.125 ± 1.6535
direct [BD], Week 24, n=58, 83, 863.214 ± 1.57173.338 ± 1.84842.903 ± 1.5970
direct [BD], Week 52/WD, n=60, 90, 892.850 ± 1.20573.344 ± 1.55743.055 ± 1.5569
indirect [BI], Baseline, n=60, 93, 907.495 ± 2.98837.079 ± 3.37887.125 ± 2.8688
indirect [BI], Week 12, n=58, 90, 877.017 ± 3.10047.600 ± 3.21316.938 ± 3.0451
indirect [BI], Week 24, n=58, 83, 867.842 ± 5.15537.747 ± 3.74206.760 ± 3.2222
indirect [BI], Week 52/WD, n=60, 90, 896.640 ± 2.71007.505 ± 3.56766.936 ± 3.4525
total [BT], Baseline, n=60, 93, 9010.716 ± 4.198910.315 ± 4.773510.526 ± 4.3571
total [BT], Week 12, n=58, 90, 879.965 ± 4.178110.830 ± 4.542410.063 ± 4.3902
total [BT], Week 24, n=58, 83, 8611.056 ± 6.495411.084 ± 5.44279.663 ± 4.4958
total [BT], Week 52/WD, n=60, 90, 899.491 ± 3.650310.849 ± 4.85139.991 ± 4.7177
Creatinine, Baseline, n=60, 93, 9061.8800 ± 13.3709166.4806 ± 15.9448362.0568 ± 12.65536
Creatinine, Week 12, n=58, 90, 8759.3042 ± 13.9274362.9408 ± 15.7144460.1628 ± 13.02866
Creatinine, Week 24, n=58, 83, 8659.7614 ± 12.9137164.5213 ± 15.9063160.6773 ± 13.02242
Creatinine, Week 52/WD, n=60, 90, 8960.4067 ± 12.5245864.6204 ± 16.0176261.3536 ± 14.38660
Uric acid, Baseline, n=60, 93, 90304.0419 ± 90.67062305.7784 ± 78.88104310.6178 ± 96.11471
Uric acid, Week 12, n=58, 90, 87302.6301 ± 86.10161301.6297 ± 74.72395303.8266 ± 87.04586
Uric acid, Week 24, n=58, 83, 86299.6561 ± 78.45023310.8726 ± 86.38513308.5352 ± 91.73313
Uric acid, Week 52/WD, n=60, 90, 89305.2315 ± 78.61596300.3079 ± 82.30325308.0262 ± 92.43123
SecondaryLaboratory Parameter of Chloride, Carbon Dioxide Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

Blood samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

Time frame:
Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Reported as:
Mean · Millimoles per Liter (mmol/L)
Laboratory Parameter of Chloride, Carbon Dioxide Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Millimoles per Liter (mmol/L)FF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Chloride, BL, n=60, 93, 90104.3 ± 1.97104.2 ± 1.85103.6 ± 1.60
Chloride, Week 12, n=58, 90, 87105.9 ± 2.05105.6 ± 2.38105.6 ± 2.14
Chloride, Week 24, n=58, 83, 86105.4 ± 2.04105.0 ± 2.44105.0 ± 2.16
Chloride, Week 52/WD, n=60, 90, 89105.6 ± 2.19105.3 ± 2.41104.8 ± 2.12
CO2 content/Bicarbonate, BL, n=60, 93, 9025.3 ± 2.0225.0 ± 1.8425.2 ± 1.95
CO2 content/Bicarbonate, Week 12, n=58, 90, 8724.9 ± 2.0124.8 ± 2.1325.4 ± 1.81
CO2 content/Bicarbonate, Week 24, n=58, 83, 8625.4 ± 2.2625.3 ± 2.3324.8 ± 2.32
CO2 content/Bicarbonate, Week 52/WD, n=60, 90, 8824.9 ± 2.0325.3 ± 2.1425.1 ± 2.04
Glucose, BL, n=60, 93, 905.6685 ± 0.886995.7826 ± 0.987535.7669 ± 1.03176
Glucose, Week 12, n=58, 90, 875.5606 ± 1.076795.7848 ± 1.014095.7647 ± 1.05233
Glucose, Week 24, n=58, 83, 865.8228 ± 1.412355.8593 ± 0.976135.8169 ± 1.43353
Glucose, Week 52/WD, n=60, 90, 895.4455 ± 1.059055.7743 ± 1.006365.8572 ± 1.17153
Potassium, BL, n=60, 93, 904.04 ± 0.2794.13 ± 0.3324.12 ± 0.338
Potassium, Week 12, n=58, 90, 874.17 ± 0.2824.17 ± 0.3664.16 ± 0.352
Potassium, Week 24, n=58, 83, 864.14 ± 0.3264.17 ± 0.3904.16 ± 0.331
Potassium, Week 52/WD, n=60, 90, 894.14 ± 0.3334.17 ± 0.3634.16 ± 0.306
Sodium, BL, n=60, 93, 90141.2 ± 1.53141.3 ± 1.66140.7 ± 1.59
Sodium, Week 12, n=58, 90, 87141.1 ± 1.62140.7 ± 1.81140.8 ± 1.47
Sodium, Week 24, n=58, 83, 86140.9 ± 1.23141.1 ± 1.89141.0 ± 1.69
Sodium, Week 52/WD, n=60, 90, 89141.3 ± 1.42141.6 ± 1.62141.2 ± 1.80
Urea/BUN, BL, n=60, 93, 905.0658 ± 1.500715.0928 ± 1.386954.7116 ± 1.12591
Urea/BUN, Week 12, n=58, 90, 875.0792 ± 1.183334.9865 ± 1.233024.7973 ± 1.37172
Urea/BUN, Week 24, n=58, 83, 865.0177 ± 1.168804.9593 ± 1.233014.8510 ± 1.24616
Urea/BUN, Week 52/WD, n=60, 90, 894.9932 ± 1.288284.9869 ± 1.411204.7120 ± 1.16694
SecondaryLaboratory Parameter of Urine Potential of Hydrogen (pH) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

Urine samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

Time frame:
Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Reported as:
Mean · pH
Laboratory Parameter of Urine Potential of Hydrogen (pH) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
pHFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Urine pH, Baseline, n=60, 93, 906.33 ± 0.7746.36 ± 0.8836.46 ± 0.852
Urine pH, Week 12, n=58, 90, 876.41 ± 0.7266.36 ± 0.7986.39 ± 0.833
Urine pH, Week 24, n=58, 83, 866.27 ± 0.7856.40 ± 0.8786.33 ± 0.807
Urine pH, Week 52/WD, n=60, 90, 896.25 ± 0.7956.50 ± 0.7756.42 ± 0.847
SecondaryLaboratory Parameter of Urine Specific Gravity (USG) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD

Urine samples were collected for measurement at the following scheduled time points: Baseline (Week -2), Week 12, Week 24 and Week 52/WD.

Time frame:
Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Reported as:
Mean · ratio of urine density to water density
Laboratory Parameter of Urine Specific Gravity (USG) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
ratio of urine density to water densityFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Urine Specific Gravity, Baseline, n=60, 93, 901.0177 ± 0.007641.0177 ± 0.008301.0173 ± 0.00734
Urine Specific Gravity, Week 12, n=58, 90, 871.0171 ± 0.007311.0167 ± 0.007891.0163 ± 0.00806
Urine Specific Gravity, Week 24, n=58, 83, 861.0174 ± 0.007951.0180 ± 0.007551.0179 ± 0.00758
Urine Specific Gravity, Week 52/WD, n=60, 90, 891.0160 ± 0.006891.0159 ± 0.007551.0156 ± 0.00811
SecondaryNumber of Participants for the Indicated Uninalysis Parameters Tested by Dipstick at Baseline (BL), Week 12, Week 24, and Week 52/WD

Urinalysis parameters included: Urine Occult Blood (UOB), Urine Glucose (UG), Urine Ketones (UK), Urine Protein (UP), and Urine Leukocyte Esterase test for detecting White Blood Cell (UWBC). The dipstick was a strip used to detect the presence or absence of these parameters in the urine sample. The dipstick test gives results in a semi-quantitative manner, and results can be read as negative (Neg), Trace (TRA), 1+, 2+, and 3+, indicating proportional concentrations in the urine sample. Data are reported as the number of participants who had neg, trace, 1+, 2+, and 3+ levels at Baseline (Week -2) and Week 52/WD.

Time frame:
Baseline (Week -2), Week 12, Week 24, and Week 52/WD
Reported as:
Number · Participants
Number of Participants for the Indicated Uninalysis Parameters Tested by Dipstick at Baseline (BL), Week 12, Week 24, and Week 52/WD
ParticipantsFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
UOB, Neg, BL, n=60, 93, 90517981
UOB, TRA, BL, n=60, 93, 90652
UOB, 1+, BL, n=60, 93, 90252
UOB, 2+, BL, n=60, 93, 90133
UOB, 3+, BL, n=60, 93, 90012
UOB, Neg, Week 12, n=58, 90, 87507975
UOB, TRA, Week 12, n=58, 90, 87245
UOB, 1+, Week 12, n=58, 90, 87423
UOB, 2+, Week 12, n=58, 90, 87231
UOB, 3+, Week 12, n=58, 90, 87023
UOB, Neg, Week 24, n=58, 83, 86497178
UOB, TRA, Week 24, n=58, 83, 86462
UOB, 1+, Week 24, n=58, 83, 86114
UOB, 2+, Week 24, n=58, 83, 86330
UOB, 3+, Week 24, n=58, 83, 86122
UOB, Neg, Week 52/WD, n=60, 90, 89547681
UOB, TRA, Week 52/WD, n=60, 90, 89442
UOB, 1+, Week 52/WD, n=60, 90, 89061
UOB, 2+, Week 52/WD, n=60, 90, 89133
UOB, 3+, Week 52/WD, n=60, 90, 89112
UG, Neg, BL, n=60, 93, 90589387
UG, TRA, BL, n=60, 93, 90201
UG, 1+, BL, n=60, 93, 90000
UG, 2+, BL, n=60, 93, 90002
UG, 3+, BL, n=60, 93, 90000
UG, Neg, Week 12, n=58, 90, 87559083
UG, TRA, Week 12, n=58, 90, 87200
UG, 1+, Week 12, n=58, 90, 87100
UG, 2+, Week 12, n=58, 90, 87001
UG, 3+, Week 12, n=58, 90, 87003
UG, Neg, Week 24, n=58, 83, 86538082
UG, TRA, Week 24, n=58, 83, 86210
UG, 1+, Week 24, n=58, 83, 86211
UG, 2+, Week 24, n=58, 83, 86100
UG, 3+, Week 24, n=58, 83, 86013
UG, Neg, Week 52/WD, n=60, 90, 89598784
UG, TRA, Week 52/WD, n=60, 90, 89033
UG, 1+, Week 52/WD, n=60, 90, 89100
UG, 2+, Week 52/WD, n=60, 90, 89001
UG, 3+, Week 52/WD, n=60, 90, 89001
UK, Neg, BL, n=60, 93, 90609390
UK, TRA, BL, n=60, 93, 90000
UK, 1+, BL, n=60, 93, 90000
UK, 2+, BL, n=60, 93, 90000
UK, 3+, BL, n=60, 93, 90000
UK, Neg, Week 12, n=58, 90, 87588986
UK, TRA, Week 12, n=58, 90, 87000
UK, 1+, Week 12, n=58, 90, 87011
UK, 2+, Week 12, n=58, 90, 87000
UK, 3+, Week 12, n=58, 90, 87000
UK, Neg, Week 24, n=58, 83, 86588386
UK, TRA, Week 24, n=58, 83, 86000
UK, 1+, Week 24, n=58, 83, 86000
UK, 2+, Week 24, n=58, 83, 86000
UK, 3+, Week 24, n=58, 83, 86000
UK, Neg, Week 52/WD, n=60, 90, 89599089
UK, TRA, Week 52/WD, n=60, 90, 89000
UK, 1+, Week 52/WD, n=60, 90, 89100
UK, 2+, Week 52/WD, n=60, 90, 89000
UK, 3+, Week 52/WD, n=60, 90, 89000
UP, Neg, BL, n=60, 93, 90557679
UP, TRA, BL, n=60, 93, 904169
UP, 1+, BL, n=60, 93, 90112
UP, 2+, BL, n=60, 93, 90000
UP, 3+, BL, n=60, 93, 90000
UP, Neg, Week 12, n=58, 90, 87528276
UP, TRA, Week 12, n=58, 90, 87557
UP, 1+, Week 12, n=58, 90, 87024
UP, 2+, Week 12, n=58, 90, 87100
UP, 3+, Week 12, n=58, 90, 87010
UP, Neg, Week 24, n=58, 83, 86507380
UP, TRA, Week 24, n=58, 83, 86785
UP, 1+, Week 24, n=58, 83, 86111
UP, 2+, Week 24, n=58, 83, 86010
UP, 3+, Week 24, n=58, 83, 86000
UP, Neg, Week 52/WD, n=60, 90, 89547068
UP, TRA, Week 52/WD, n=60, 90, 8951517
UP, 1+, Week 52/WD, n=60, 90, 89142
UP, 2+, Week 52/WD, n=60, 90, 89012
UP, 3+, Week 52/WD, n=60, 90, 89000
UWBC, Neg, BL, n=60, 93, 90537982
UWBC,TRA, BL, n=60, 93, 90000
UWBC,1+, BL, n=60, 93, 90373
UWBC,2+, BL, n=60, 93, 90332
UWBC,3+, BL, n=60, 93, 90143
UWBC,Neg, Week 12, n=58, 90, 87527377
UWBC,TRA, Week 12, n=58, 90, 87000
UWBC,1+, Week 12, n=58, 90, 87257
UWBC,2+, Week 12, n=58, 90, 87353
UWBC,3+, Week 12, n=58, 90, 87170
UWBC,Neg, Week 24, n=58, 83, 86507078
UWBC,TRA, Week 24, n=58, 83, 86000
UWBC,1+, Week 24, n=58, 83, 86467
UWBC,2+, Week 24, n=58, 83, 86251
UWBC,3+, Week 24, n=58, 83, 86220
UWBC,Neg, Week 52/WD, n=60, 90, 89527578
UWBC,TRA, Week 52/WD, n=60, 90, 89000
UWBC,1+, Week 52/WD, n=60, 90, 89462
UWBC,2+, Week 52/WD, n=60, 90, 89357
UWBC,3+, Week 52/WD, n=60, 90, 89142
SecondaryChange From Baseline in the 24-hour Urinary Cortisol Excretion

Urine samples were collected for measurement of urinary cortisol excretion at the following scheduled time points: Baseline (Week 0), Week 24, and Week 52/WD. The 24-hour urinary cortisol excretion was calculated by multiplying the total volume of urine by the concentration of urinary cortisol. Cortisol is a hormone released from the adrenal gland that helps in fat, protein, and carbohydrate metabolism. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline.

Time frame:
Baseline (Week 0), Week 24, and Week 52/WD
Reported as:
Geometric mean · Nanomoles (nmol)/24 hours
Change From Baseline in the 24-hour Urinary Cortisol Excretion
Nanomoles (nmol)/24 hoursFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Week 24, n=19, 20, 281.0218 ± 42.3091.0602 ± 64.8250.9698 ± 67.211
Week 52/WD, n=18, 19, 300.8956 ± 48.2311.0802 ± 73.9120.8190 ± 41.301
SecondaryChange From Baseline in Blood Pressure

Blood pressure measurement included systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Baseline (Week 0), Weeks 12, 24 and Week 52/WD. Blood pressure was measured in a sitting position after a participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (Week 0), Week 12, Week 24, and Week 52/WD
Reported as:
Mean · Millimeters of Mercury (mmHg)
Change From Baseline in Blood Pressure
Millimeters of Mercury (mmHg)FF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
SBP, Week 12, n=58, 90, 88-1.6 ± 9.541.2 ± 11.420.7 ± 13.01
SBP, Week 24, n=58, 83, 86-0.7 ± 11.76-1.6 ± 12.880.1 ± 9.39
SBP Week 52/WD, n=60, 92, 89-1.5 ± 9.340.5 ± 11.950.9 ± 11.66
DBP, Week 12, n=58, 90, 88-0.3 ± 8.091.0 ± 8.63-2.3 ± 9.28
DBP, Week 24, n=58, 83, 86-0.7 ± 8.460.5 ± 9.43-1.1 ± 7.82
DBP, Week 52/WD, n=60, 92, 89-0.1 ± 8.551.5 ± 10.13-0.1 ± 9.20
SecondaryChange From Baseline in Heart Rate (HR)

Heart rate was measured in a sitting position after a participant was kept at rest for at least 5 minutes at Baseline (Week 0), Weeks 12, 24 and Week 52/WD. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (Week 0), Week 12, Week 24, and Week 52/WD
Reported as:
Mean · Beats/Minute
Change From Baseline in Heart Rate (HR)
Beats/MinuteFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Week 12, n=58, 90, 880.9 ± 12.27-0.6 ± 9.021.3 ± 8.54
Week 24, n=58, 83, 860.1 ± 9.240.1 ± 9.181.1 ± 9.97
Week 52/WD, n=60, 92, 89-1.2 ± 10.91-1.4 ± 9.621.1 ± 9.10
SecondaryNumber of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings

A 12-lead ECG was recorded in a supine position after the participant was kept at rest in this position for at least 5 minutes at assessment time points (Baseline\[Week -2\], Week 12, 24 and Week 52/WD) in the treatment period. Data are presented for clinically significant (CS) as well as not clinically significant (NCS) abnormal (Abn) findings. Any abnormal ECG, including those that worsen from Baseline, and determined clinically significant by the assessment of the investigator were recorded as CS.

Time frame:
Week 12, Week 24, and Week 52/WD
Reported as:
Number · Participants
Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings
ParticipantsFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Baseline, Abn NCS, n=60, 93, 90192211
Baseline, Abn CS, n=60, 93, 90000
Week 12, Abn NCS, n=58, 90, 88111710
Week 12, Abn CS, n=58, 90, 88000
Week 24, Abn NCS, n=58, 83, 8612189
Week 24, Abn CS, n=58, 83, 86000
Week 52/WD, Abn NCS, n=60, 90, 89101612
Week 52/WD, Abn CS, n=60, 90, 89020
SecondaryNumber of Participants With Severe Asthma Exacerbation During the Study Treatment

A severe asthma exacerbation is defined as the deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. Courses of corticosteroids separated by 1 week or more were treated as separate severe exacerbations.

Time frame:
Baseline up to Week 52
Reported as:
Number · Participants
Number of Participants With Severe Asthma Exacerbation During the Study Treatment
ParticipantsFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Number of Participants With Severe Asthma Exacerbation During the Study Treatment3916
SecondaryChange From Baseline in Diary Data - Morning (AM) Peak Expiratory Flow (PEF) and Evening (PM) PEF During the Study Treatment

Change from Baseline in AM and PM PEF at 52 weeks of evaluation period during study treatment was recorded in the dairy record card. The Baseline value was calculated as the mean of all available data recorded during the7 days immediately prior to the treatment start date (including Day 1: Day 1 is treatment start date). The PEF is defined as the greatest rate of airflow that can be achieved during forced exhalation beginning with the lungs fully inflated.

Time frame:
Baseline up to Week 52
Reported as:
Mean · Litres per Minute (L/min)
Change From Baseline in Diary Data - Morning (AM) Peak Expiratory Flow (PEF) and Evening (PM) PEF During the Study Treatment
Litres per Minute (L/min)FF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
PEF AM, Week 0-5218.29 ± 36.30423.98 ± 38.66812.38 ± 32.295
PEF PM, Week 0-5220.23 ± 35.27426.29 ± 40.51015.64 ± 30.772
SecondaryChange From Baseline in Asthma Symptom Score During the Study Treatment

The Baseline value was calculated as the mean of all available data recorded during the 7 days immediately prior to Visit 2 (treatment assignment visit). Participants entered their asthma symptom score in the patient diary twice daily (morning and evening). Daytime asthma symptom scores: 0-no asthma symptoms, 1-one episode of short-time asthma symptoms, 2-two or more episodes of short-time asthma symptoms, 3-asthma symptoms occurring during most part of daytime without interference with daily life activities, 4-asthma symptoms occurring during most part of daytime with interference with daily life activities, 5-severe asthma symptoms that disable working or daily life activities. Nighttime asthma symptom scores: 0-no asthma symptoms, 1-one awakening due to asthma symptoms, 2-two or more awakenings due to asthma symptoms, 3-asthma symptoms almost prevented the participant from sleeping, 4-severe asthma symptoms completely prevented from sleeping.

Time frame:
Baseline up to Week 52
Reported as:
Mean · Scores on a scale
Change From Baseline in Asthma Symptom Score During the Study Treatment
Scores on a scaleFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Change From Baseline in Asthma Symptom Score During the Study Treatment-0.14 ± 0.638-0.14 ± 0.856-0.19 ± 0.771
SecondaryChange From Baseline in the Percentage of Symptom-free 24-hour Periods During the Study Treatment

Participants who were symptom free for 24-hours were assessed. Change from Baseline is calculated as the value at Week 52 minus the value at Baseline.

Time frame:
Baseline up to Week 52
Reported as:
Mean · Percentage of symptom-free days
Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the Study Treatment
Percentage of symptom-free daysFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the Study Treatment6.79 ± 20.3826.51 ± 28.2908.19 ± 26.975
SecondaryChange From Baseline in the Percentage of Rescue-free 24-hour Periods

The time span during which the participants did not have to take any rescue medication (medication intended to relieve symptoms immediately) was considered as a rescue free period. Change from Baseline is calculated as the value at Week 52 minus the value at Baseline.

Time frame:
Baseline up to Week 52
Reported as:
Mean · Percentage of rescue free 24-hour period
Change From Baseline in the Percentage of Rescue-free 24-hour Periods
Percentage of rescue free 24-hour periodFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Week 0-12, n=60, 93, 9097.94 ± 9.55395.51 ± 16.42792.79 ± 17.462
Week 13-24, n=58, 91, 8897.60 ± 7.52195.94 ± 13.47794.35 ± 16.990
Week 25-36, n=58, 84, 8797.99 ± 8.75795.24 ± 14.68594.14 ± 15.713
Week 37-52, n=57, 79, 8698.38 ± 7.25395.71 ± 13.38295.13 ± 14.705
Week 0-52, n=60, 93, 9098.01 ± 7.73695.76 ± 13.55694.28 ± 15.169
SecondaryNumber of Rescue Medication Inhalations

Salbutamol inhaler was used as the rescue medication. Participants entered the number of rescue medication inhalations in the patient diary twice daily (morning and evening).

Time frame:
Baseline up to Week 52
Reported as:
Mean · Number of inhalations
Number of Rescue Medication Inhalations
Number of inhalationsFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Week 0-12, n=60, 93, 905.15 ± 31.2887.32 ± 27.66713.42 ± 43.889
Week 13-24, n=58, 91, 885.12 ± 19.0946.65 ± 23.25712.56 ± 54.154
Week 25-36, n=58, 84, 876.02 ± 36.3587.45 ± 25.05814.01 ± 70.642
Week 37-52, n=57, 79, 867.75 ± 50.8517.73 ± 22.28517.78 ± 97.092
Week 0-52, n=60, 93, 9023.28 ± 132.46727.13 ± 90.03856.23 ± 253.508

Adverse events

Collected over On-treatment non-serious adverse events (AEs), defined as those events occurring while participants were on treatment, up to and including the day after the last dose in each treatment period (up to 52 weeks), are reported. SAEs, defined as those events o. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FF/GW642444 100/25 µg—4/60 (6.7%)52/60 (86.7%)
FF/GW642444 200/25 µg—7/93 (7.5%)77/93 (82.8%)
FF 100 µg—1/90 (1.1%)72/90 (80%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders2/600/930/90
PneumoniaInfections and infestations1/601/930/90
Chronic sinusitisInfections and infestations1/600/930/90
TonsillitisInfections and infestations1/600/930/90
Nasal septum deviationRespiratory, thoracic and mediastinal disorders1/600/930/90
Rhinitis hypertrophicRespiratory, thoracic and mediastinal disorders1/600/930/90
Colitis ischaemicGastrointestinal disorders1/600/930/90
Dermatitis atopicSkin and subcutaneous tissue disorders0/600/931/90
DiverticulitisInfections and infestations0/601/930/90
Nasal polypsRespiratory, thoracic and mediastinal disorders0/601/930/90
Most frequent other events
Showing 10 of 19
Most frequent other events
EventFF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µg
NasopharyngitisInfections and infestations37/6057/9349/90
BronchitisInfections and infestations8/6018/9312/90
Oral candidiasisInfections and infestations3/6013/933/90
PharyngitisInfections and infestations7/6012/9312/90
GastroenteritisInfections and infestations7/600/937/90
InfluenzaInfections and infestations2/609/937/90
DysphoniaRespiratory, thoracic and mediastinal disorders5/606/936/90
HeadacheNervous system disorders5/604/935/90
AsthmaRespiratory, thoracic and mediastinal disorders0/606/937/90
EczemaSkin and subcutaneous tissue disorders4/603/933/90

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µgTotal
Mean51.3 ± 13.7452.6 ± 15.0546.8 ± 15.4650.1 ± 15.06
Gender
Gender(Participants)FF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µgTotal
Female384954141
Male224436102
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FF/GW642444 100/25 µgFF/GW642444 200/25 µgFF 100 µgTotal
Asian - Japanese Heritage609390243
08

Study locations

30 sites
  • GSK Investigational Site
    Chiba, 277-0863, Japan
  • GSK Investigational Site
    Fukuoka, 802-0083, Japan
  • GSK Investigational Site
    Fukuoka, 816-0813, Japan
  • GSK Investigational Site
    Gifu, 501-6062, Japan
  • GSK Investigational Site
    Gunma, 373-0021, Japan
  • GSK Investigational Site
    Hiroshima, 730-0844, Japan
  • GSK Investigational Site
    Hiroshima, 732-0062, Japan
  • GSK Investigational Site
    Hiroshima, 739-0402, Japan
  • GSK Investigational Site
    Hyogo, 665-0827, Japan
  • GSK Investigational Site
    Hyogo, 670-0046, Japan
  • GSK Investigational Site
    Hyogo, 672-8064, Japan
  • GSK Investigational Site
    Ibaraki, 302-0022, Japan
  • GSK Investigational Site
    Kanagawa, 231-8682, Japan
  • GSK Investigational Site
    Kanagawa, 253-0041, Japan
  • GSK Investigational Site
    Kyoto, 601-1495, Japan
  • GSK Investigational Site
    Kyoto, 615-8087, Japan
  • GSK Investigational Site
    Miyagi, 983-0824, Japan
  • GSK Investigational Site
    Miyagi, 983-8520, Japan
  • GSK Investigational Site
    Nagano, 390-0303, Japan
  • GSK Investigational Site
    Nagano, 390-8510, Japan
  • GSK Investigational Site
    Okayama, 700-0862, Japan
  • GSK Investigational Site
    Okayama, 701-0304, Japan
  • GSK Investigational Site
    Okayama, 714-0081, Japan
  • GSK Investigational Site
    Osaka, 545-8586, Japan
  • GSK Investigational Site
    Osaka, 569-1192, Japan
  • GSK Investigational Site
    Osaka, 589-0022, Japan
  • GSK Investigational Site
    Tokyo, 105-0004, Japan
  • GSK Investigational Site
    Tokyo, 134-0083, Japan
  • GSK Investigational Site
    Tokyo, 185-0014, Japan
  • GSK Investigational Site
    Toyama, 937-0066, Japan
09

References and documents

Publications

  • O'Byrne PM, Jacques L, Goldfrad C, Kwon N, Perrio M, Yates LJ, Busse WW. Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Respir Res. 2016 Nov 24;17(1):157. doi: 10.1186/s12931-016-0473-x. PubMed 27881132 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2010
First posted
Nov 22, 2010
Start
Jul 2010
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Results first posted
Aug 9, 2013
Last update
Jan 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01244984
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 22, 2010
Start date
Jul 2010
Primary completion
Jan 2012
Completion
Jan 2012
Results posted
Aug 9, 2013
Last update
Jan 11, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Vilanterol

Start the discussion